Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 3 boards, counting each seat separately. Longest: Sagimet Biosciences Inc., 3 years.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Ardelyx Inc. | Grant or award | +26,455 | — | — |
| Jun 18, 2025 | Ardelyx Inc. | Grant or award | +15,235 | — | — |
| Apr 28, 2025 | Ardelyx Inc. | Grant or award | +42,056 | — | — |
| Dec 10, 2024 | Gilead Sciences Inc. | Option exercise | +3,820 | — | — |
| Dec 10, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −1,771 | $92.34 | $163,534 |
| Nov 27, 2024 | Gilead Sciences Inc. | Option exercise | +57,294 | $57.92 | $3,318,468 |
| Nov 27, 2024 | Gilead Sciences Inc. | Option exercise | +88,119 | $65.38 | $5,761,220 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −57,294 | $91.79 | $5,259,016 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −88,119 | $92.00 | $8,106,948 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −5,200 | $91.80 | $477,360 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −3,199 | $91.80 | $293,668 |
| Nov 27, 2024 | Gilead Sciences Inc. | Open-market sale | −10,399 | $92.00 | $956,708 |
| Nov 6, 2024 | Gilead Sciences Inc. | Option exercise | +25,000 | $57.92 | $1,448,000 |
| Nov 6, 2024 | Gilead Sciences Inc. | Open-market sale | −20,590 | $91.50 | $1,883,985 |
| Nov 6, 2024 | Gilead Sciences Inc. | Open-market sale | −5,000 | $91.50 | $457,500 |
Questions about Merdad Parsey
What boards is Merdad Parsey on?
Merdad Parsey sits on the boards of Ardelyx Inc., ArriVent BioPharma Inc. and Sagimet Biosciences Inc.
How long has Merdad Parsey served on boards?
Our records show at least 6 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.